Literature DB >> 3031718

Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans--III. Hypothalamo-pituitary-adrenocortical axis.

G Laakmann, M Wittmann, H W Schoen, K Zygan, A Weiss, R Meissner, O A Mueller, G K Stalla.   

Abstract

In this report the effects of various receptor blockers on the desimipramine (DMI)-induced cortisol (ACTH) secretion in healthy male subjects are presented. Each trial consisted of two administrations: one of DMI i.v. alone and one of DMI i.v. in combination with the respective receptor blocker, i.e. methysergide (serotonin (5-HT) receptor blocker), propranolol (beta receptor blocker), phentolamine (alpha-1/alpha-2 receptor blocker), yohimbine (alpha-2 greater than alpha-1 receptor blocker), and prazosin (alpha-1 receptor blocker). In addition, the effect of prazosin on DMI-induced ACTH stimulation was examined. DMI-induced cortisol stimulation was not significantly different after DMI alone (n = 12) from that after three days pretreatment with methysergide (12 mg p.o.) in another group of subjects (n = 12). Neither the combination of DMI plus propranolol (15 mg i.v. n = 18, incomplete block design) nor that of DMI plus phentolamine (60 mg i.v. n = 12) had a significant influence on DMI-induced cortisol secretion. Following combined administration with yohimbine (10 mg i.v.), cortisol secretion was higher compared to that after DMI alone in the same group (n = 6). DMI-induced cortisol secretion was significantly lower (p less than 0.01) following combined administration with prazosin (1 mg p.o. n = 12), as was DMI-induced ACTH secretion (p less than 0.05) in these subjects. The findings of these trials, especially those of the prazosin trial, indicate that DMI-induced stimulation of cortisol and ACTH secretion is attributable to the noradrenaline (NA) reuptake inhibiting effect of DMI, and that the stimulus is transmitted with the aid of noradrenergic alpha-1 receptors. Alpha-2 receptors possibly exert a negative influence on this effect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3031718     DOI: 10.1016/0306-4530(86)90008-9

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  7 in total

Review 1.  Measuring the activity of brain adrenergic receptors in man.

Authors:  S al-Damluji
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

2.  The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects.

Authors:  Stefan Cohrs; Cornelia Röher; Wolfgang Jordan; Andreas Meier; Gerald Huether; Wolfgang Wuttke; Eckart Rüther; Andrea Rodenbeck
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

3.  Oxaprotiline enantiomers stimulate ACTH and corticosterone secretion in the rat.

Authors:  E Przegaliński; B Budziszewska; A Grochmal
Journal:  J Neural Transm Gen Sect       Date:  1991

4.  Lithium increases 5-HT-mediated prolactin release.

Authors:  S L McCance; P R Cohen; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Ziprasidone decreases cortisol excretion in healthy subjects.

Authors:  Andreas Meier; Anna-Catharina Neumann; Wolfgang Jordan; Gerald Huether; Andrea Rodenbeck; Eckart Rüther; Stefan Cohrs
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

6.  Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects.

Authors:  Stefan Cohrs; Kathrin Pohlmann; Zhenghua Guan; Wolfgang Jordan; Andreas Meier; Gerald Huether; Eckart Rüther; Andrea Rodenbeck
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

7.  Sex differences in the pituitary-adrenal response following acute antidepressant treatment in sheep.

Authors:  Jillian H Broadbear; Lisa C Hutton; Iain J Clarke; Benedict J Canny
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.